Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2021

Autores

Rebelo, R (Autor) Outra; Polonia, B (Autor) Outra; Santos, LL (Autor) Outra; Helena Vasconcelos, MH (Autor) FFUP; Xavier, CPR (Autor) Outra

Revista

Título: Pharmaceuticals

Vol. 14

Página Final: 280

ISSN: 1424-8247

Editora: MDPI

Indexação

ISI Web of Knowledge - 0 Citações

Scopus - 0 Citações

Outras Informações

ID Authenticus: P-00T-QBV

DOI: 10.3390/ph14030280

Abstract (EN): Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a five-year survival rate of around 5%. Treatment of PDAC is still a major challenge, with cytotoxic chemotherapy remaining the basis of systemic therapy. However, no major advances have been made recently, and therapeutic options are limited and highly toxic. Thus, novel therapeutic options are urgently needed. Drug repurposing is a strategy for the development of novel treatments using approved or investigational drugs outside the scope of the original clinical indication. Since repurposed drugs have already completed several stages of the drug development process, a broad range of data is already available. Thus, when compared with de novo drug development, drug repurposing is time-efficient, inexpensive and has less risk of failure in future clinical trials. Several repurposing candidates have been investigated in the past years for the treatment of PDAC, as single agents or in combination with conventional chemotherapy. This review gives an overview of the main drugs that have been investigated as repurposing candidates, for the potential treatment of PDAC, in preclinical studies and clinical trials.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 35